KKR Real Estate Finance Trust Inc. Q1 FY2025 earnings call

Market and Positioning

• Since the last earnings call, market volatility and recession expectations have increased post-tariff implementations, but real estate is better positioned. No corporate maturities until 2030 with ample liquidity over $700 million.

Loan Activity

• Closed four loans totaling $376 million, 80% secured by Class A multi-family properties. Repayments in the quarter were $180.4 million, net fundings $220.2 million.

Portfolio Diversification

• Actively looking to diversify portfolio and add duration, focusing on European lending and US CMBS. Pipeline over $30 billion, the largest ever and high quality.

Loan Downgrades

• Downgraded two loans: Raleigh, NC multifamily from 4 to 5, Boston life science from 3 to 4. Engaged in workout discussions for downgraded loans.

Life Science Exposure

• 12% of loan portfolio in life science, with one REO property. Executed lease in Seattle Life Science REO. Focus on high-quality, purpose-built life science assets.

Financing Actions

• Upsized corporate revolver to $660 million and refinanced Term Loan B to 7-year facility. Repurchased $10 million of stock in Q1, total repurchased in past two quarters $20 million.

In the first quarter of 2025, KKR Real Estate Finance Trust reported a net loss of $10.6 million or 15 cents per share. Book value as of March 31 was $14.44 per share. Distributable earnings were $17 million or 25 cents per share, aligning with the 25 cent per share dividend. The firm closed four loans totaling $376 million, with 80% secured by Class A multi-family properties, having a weighted average LTV of 69% and a coupon of SOFR plus 277 basis points. Repayments in the quarter were $180.4 million, and net fundings totaled $220.2 million. The portfolio grew 4% quarter over quarter.

Repayments and Pipeline

• Repayments expected to exceed $1 billion, tracking above initial expectations. Pipeline over $30 billion, largest ever.

Investment Focus

• Actively looking to reinvest repayments into new originations. Focus on European lending and US CMBS for diversification. Expect to recycle capital into new opportunities throughout the year.

Loan Downgrades

• Downgraded Raleigh, NC multifamily and Boston life science loans. Evaluating scenarios for Raleigh loan, potential ownership position. Cyclical headwinds in life science sector, potential impact from economic downturn or NIH funding cuts. Market volatility and uncertainty affecting real estate recovery.

Q: Concerns about macro environment and specific portfolio risks; dividend policy.

A: Macro environment watched for job market and unemployment impact; specific properties like West Coast industrial and leasing decision slowdown; dividend policy balanced, considering REO potential and stock buybacks.

Q: Europe origination plans; repayments impact of tariffs.

A: Actively originating in Western Europe and UK; early to tell impact of tariffs on repayments, but market still functioning with liquidity.

Q: Raleigh multifamily downgrade reasons; life science capital patience.

A: Raleigh multifamily downgrade due to lack of rental growth and near term maturity; life science exposure in purpose-built assets, patient as sector recovers.

Q: New lending opportunities vs past; life science loan values.

A: New opportunities with lower valuations, less transitional assets, more stabilized lending; life science loans not expected to migrate further downgrade, but need lease up.

Q: Net portfolio growth and life science loan risks.

A: Approaching target leverage, expect incremental growth; life science loans have risk but strong sponsorship and locations.